Warburg Research set a €100.00 ($116.28) target price on Merck KGaA (FRA:MRK) in a research report report published on Wednesday, September 12th. The brokerage currently has a neutral rating on the healthcare company’s stock.
Several other equities analysts also recently weighed in on MRK. JPMorgan Chase & Co. reaffirmed a neutral rating and issued a price objective on shares of Merck KGaA in a research note on Tuesday, September 11th. Sanford C. Bernstein set a €105.00 ($122.09) price target on Merck KGaA and gave the stock a buy rating in a research report on Thursday, August 9th. Goldman Sachs Group set a €92.00 ($106.98) price target on Merck KGaA and gave the stock a neutral rating in a research report on Tuesday, September 4th. Barclays set a €70.00 ($81.40) price target on Merck KGaA and gave the stock a sell rating in a research report on Friday, August 24th. Finally, UBS Group set a €115.00 ($133.72) price target on Merck KGaA and gave the stock a buy rating in a research report on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of €98.71 ($114.78).
Merck KGaA stock traded down €1.40 ($1.63) during mid-day trading on Wednesday, reaching €88.04 ($102.37). 396,202 shares of the company were exchanged. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Article: What is a stock split?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.